In July 2018, the National Biomedical Research Institute (INRB), in the Democratic Republic of Congo (DRC), set up a pathogen genomics laboratory which allowed us to confirm epidemics of Ebola Virus Disease in the country and to establish epidemiological links between confirmed cases (1-3).
“Our compound neutralizes antibiotics in the large intestines and prevents gut microbiota disruption. Could we collaborate on its clinical development?” That was the question that brought the French biotech company Da Volterra into COMBACTE.
Register to Nature Portfolio Microbiology Community
The Nature Portfolio Microbiology Community provides a forum for the sharing and discussion of ideas and opinions about microbiology. Through posts, discussion, image and video content, the community space can be used by members to communicate with each other, and with editors, about topics ranging from the science itself through to policy, society and day to day life. It is also a place to learn more about the activities of Nature Microbiology's editors and the policies and practices of the journal.